急性髓细胞白血病10.pdfVIP

Leukemia Research 35 (2011) 301–304 Contents lists available at ScienceDirect Leukemia Research j o u rn al h omepage: w w w. elsev /locate/leu kres Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens Samantha L. Price a , Jeffrey E. Lancet b , Timothy J. George a , Gene A. Wetzstein a , Alan F. List b , Viet Q. Ho a , Hugo F. Fernandez c , Javier Pinilla-Ibarz b , Mohamed A. Kharfan-Dabaja c , Rami S. Komrokji b,∗ a Department of Pharmacy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA b Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA c Department of Blood and Bone Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA a r t i c l e i n f o a b s t r a c t Article history: There is no standard salvage regimen for AML. We retrospectively compared two commonly used regi- Received 16 June 2010 mens at our institution: CLAG and MEC. The complete response rate (CR) was 37.9% for CLAG (n = 97) and Received in revised form 17 August 2010 23.8% for MEC (n = 65) (P = 0.048), with median overall survival (OS) of 7.3 and 4.5 months, respectively Accepted 9 September 2010 (P = 0.05). In primary refractory disease, CR was 45.5% for CLAG and 22.2% for MEC (P = 0.09), with median Available online 24 November 2010 OS of 11 and 4.5 months, respectively (P = 0.07). In first relapse, CR was 36.8% and 25.9% (P